Boron-containing compounds are essential micronutrients for animals and plants
despite their low-level natural occurrence. They can strengthen the cell walls of the plants and
they play important role in supporting bone health. However, surprisingly, boron-containing
compounds are seldom found in pharmaceutical drugs. In fact, there are no inherent
disadvantages reported so far in terms of the incorporation of boron into medicines. Indeed,
drugs based on boron-containing compounds, such as tavaborole (marked name Kerydin) and
bortezomib (trade name Velcade) have been investigated and they are used in clinical
treatment. In addition, following the advanced development of boron neutron capture therapy
and a new emerging proton boron fusion therapy, more boron-containing medicinals are to be
expected. This review discusses the current status and perspectives of delivery strategy for
boron-containing drugs.
Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives
